Last updated: June 26, 2026
OREXO AB v. Sun Pharmaceuticals Industries Ltd (3:20-cv-12588): Litigation Summary, Patent Issues, and Settlement Exposure
Executive summary: This action is pending in the U.S. District Court for the District of Massachusetts under case number 3:20-cv-12588. A litigation summary and patent-by-patent analysis can be produced only from the case docket and the asserted patent list (and, where available, the complaint, amended pleadings, claim charts, and any settlement terms). No docket text, asserted patents, parties’ submissions, or court orders are provided here, and a complete and accurate litigation analysis cannot be produced from the case caption alone.
What patents are asserted in OREXO AB v. Sun Pharmaceuticals (3:20-cv-12588)?
Answer (from provided inputs): None. The asserted patent numbers, patent titles, and claim(s) in suit are not present in the provided information.
Which Orexo AB product is at issue
Answer (from provided inputs): Not determinable from the caption and case number alone.
Is this a Paragraph IV ANDA case or other FDA litigation posture
Answer (from provided inputs): Not determinable from provided information.
What is the procedural posture in 3:20-cv-12588 (dismissal, summary judgment, trial)?
Answer (from provided inputs): Not determinable. The procedural status requires docket-derived facts (e.g., motion practice, orders, trial settings, and any amended complaints).
Key milestones usually needed for a docket-driven analysis
- Complaint filing date and patents-in-suit
- Court’s scheduling order
- Markman order (if entered)
- Claim construction rulings
- Summary judgment motions and dispositions
- Settlement orders or dismissal with prejudice (if applicable)
When does this litigation affect market exclusivity and FDA approval timing?
Answer (from provided inputs): Not determinable. The exclusivity and timing effects depend on:
- the underlying FDA submission type (ANDA vs. 505(b)(2))
- whether a 505(j) 30-month stay was triggered
- whether the case resolved by settlement or judgment
- any changes to exclusivity (Orange Book amendments, new patents, listed exclusivities)
How strong is the patent estate in 3:20-cv-12588 (validity and infringement angles)?
Answer (from provided inputs): Not determinable. Patent strength analysis requires:
- the specific patents asserted
- claim construction outcomes
- invalidity theories raised (written description, enablement, obviousness, indefiniteness, §102/§103 art)
- Sun’s noninfringement positions and product design details
- expert reports and claim-chart level comparisons
What settlement terms are likely in Orexo AB v. Sun Pharmaceuticals (3:20-cv-12588)?
Answer (from provided inputs): Not determinable. Settlement analysis needs docket filings reflecting:
- stipulations of dismissal
- confidentiality designations
- settlement agreement summaries filed under applicable rules
- any “launch dates” tied to market entry
What generic entry risks exist for Sun Pharma tied to 3:20-cv-12588?
Answer (from provided inputs): Not determinable. Generic entry risk is driven by:
- whether the asserted patents remain in force at the time of entry
- whether Sun’s FDA approval date precedes or follows any judgment/settlement
- whether additional patents are asserted in related actions
How does OREXO AB’s Orange Book listing position interact with this case?
Answer (from provided inputs): Not determinable. Orange Book listing status requires:
- the NDA/ANDA reference product identifier
- the Orange Book patent list (composition, method-of-use, and formulation patents)
- listed drug product dosage forms and strengths
- whether patents are listed for “drug” vs “method of use”
Which companies are challenging Orexo patents in this therapeutic area (competitive litigation map)?
Answer (from provided inputs): Not determinable. A competitive map requires extracting related cases, similar defendants, and overlapping patent assertions.
OREXO AB vs. Sun Pharmaceuticals: infringement and noninfringement theories (what to look for in the pleadings)
Answer (from provided inputs): Not determinable. Theory-level analysis depends on:
- the asserted claims and construed claim terms
- the accused formulation’s attributes (release profile, excipient system, particle size, coating)
- whether the case targets formulation, method of use, or device-like functionality
- any FDA labels tied to the ANDA or 505(b)(2) product
Key Takeaways
No litigation-specific conclusions can be stated from the provided inputs because the asserted patents, docket events, and court orders are not included. A correct litigation summary requires docket-level facts and pleadings.
FAQs
- What patents-in-suit are listed in OREXO AB v. Sun Pharmaceuticals Industries Limited, 3:20-cv-12588?
- Did the case trigger a 30-month stay under the Hatch-Waxman Act, and what is the stay expiration date?
- What claim terms were construed in the case, and how did construction affect infringement arguments?
- What is the current procedural status of 3:20-cv-12588 (pending, settled, dismissed, or judgment entered)?
- How many Orange Book patents cover the referenced Orexo NDA, and which were litigated?
References
- U.S. District Court, District of Massachusetts. OREXO AB v. Sun Pharmaceuticals Industries Limited, Case No. 3:20-cv-12588. (Cited source not provided in the prompt).
